BMS HCV drug hit by German value assessor
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's first in class Daklinza (daclatasvir) gives no proven added benefit for hepatitis C patients compared to other therapies, according to the German HTA, IQWiG. The firm has failed to come up with the data needed to prove the drug is better than dual therapy with peginterferon alfa and ribavirin, or triple therapy with peginterferon alfa and ribavirin plus a protease inhibitor (boceprevir or telaprevir), it said.
You may also be interested in...
Australian Industry Maps Path To Better Use Of Real World Evidence
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
Decision On Covid-19 TRIPS Waiver Postponed
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Need a specific report? 1000+ reports available
Buy Reports